Compare Procter & Gamble Co (PG) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs Smith & Nephew plc — how do they compare? Procter & Gamble Co trades at $149.49 (market cap $344.87B), while Smith & Nephew plc trades at $29.95 (market cap $12.71B). The key difference: Procter & Gamble Co is far larger — about 27.1× Smith & Nephew plc's market cap, and Procter & Gamble Co pays the higher dividend (2.94%). Which is the better fit depends on your goals.
| PG | SNN | |
|---|---|---|
Market Cap | $344.87B | $12.71B |
Volume | 6,423,436 | — |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $38.70 |
52-Week Low | $138.10 | $28.73 |
Enterprise Value | $370.34B | $15.48B |
Dividend Yield | 2.94% | 2.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $149.15, showing minimal daily movement. The stock exhibits neutral technical signals with support near $147 and resistance at $150. Fundamentally, PG maintains stable revenue near $84.3 billion and strong net income margins above 19%, supported by consistent earnings beats. Recent news highlights its dividend reliability amid market volatility, with a 69-year track record of increases. Analyst consensus is bullish with a $160.50 price target, though valuation multiples trade at premiums to peers.
PG offers steady growth with dividend safety but faces near-term headwinds from premium valuations and modest revenue expansion. Upside depends on execution of supply chain efficiencies and sustained consumer demand. Risks include competitive pressures and economic sensitivity. Institutional ownership trends show mixed positioning, reflecting cautious optimism.
SNN trades at $30.21, down 1.24% today, with a bearish technical signal and mixed earnings history. Revenue grew to $5.81B in 2024 with net income of $412M, while valuation ratios like P/E of 21.25 and P/S of 2.15 suggest moderate pricing. Recent news highlights product launches in robotics and wound care, supporting growth initiatives.
Outlook is cautiously optimistic with strong cash flow and analyst buy ratings at 27%, but risks include earnings misses and rising debt. The stock offers potential from operational improvements, though investor sentiment remains divided amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
